Descargar

Trombo embolismo pulmonar y hepatitis toxica fulminante en la persona transexual (página 2)

Partes: 1, 2

  • 18. Moller S, Iversen P y Franzmann M B: F l u t a m i d e -induced liver failure. J Hepatol 1990; 10: 346-9.

  • 19. Moller S, Iversen P, Franzmann MB. Flutamide-induced liver failure. J Hepatol 1990; 10: 346.

  • 20. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354: 731-739.

  • 21. Okaneya T, Murata Y, Kinebuchi Y. Fatal hepatic failure following hepatitis caused by flutamide: a case report. Nippon Hinyo kika Gakkai Zasshi 1999; 90: 590-3.

  • 22. Pontiroli L, Sartori M, Pittau S, Morelli S, Boldorini R, Albano E. Flutamide-induced acute hepatitis: investigation on the role of immunoallergic mechanisms. Ital J Gastroenterol Hepatol 1998; 30: 310-4.

  • 23. Prattichizzo F A: Acute cholestatic hepatitis secondary to flutamide therapy. Am J Med 1994; 96: 3 9 2 – 3.

  • 24. Pu YS, Liu CM, Kao JH, Chen J, Lai MK. Antiandrogen hepatotoxicity in patients with chronic viral hepatitis. Eur Urol 1999; 36: 293-297.

  • 25. Rodríguez Gómez SJ, Martínez Moreno J, Martín Arribas MI, Pérez Villoria A, De la Serna Higuera C, Betancourt González A. Fallo hepático fulminante inducido por flutamida. Rev Esp Enferm Dig 2000; 92: 411.

  • 26. Rosenthal SA, Linstadt DE, Leibenhaut MH, Andras EJ, Brooks CP, Stickney DR, et al. Flutamide associated liver toxicity during treatment with total androgen suppression and radiation therapy for prostate cancer. Radiology 1996; 199: 451-455.

  • 27. Rosman A S, Frissora-Rodeo C, Marshall A T, Reiter B P y Paronetto F: Cholestatic hepatitis following flutamide. Dig Dis Sci 1993; 38: 1756-9.

  • 28. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: A French population-based study. Hepatology 2002; 36: 451-459.

  • 29. Takashima E, Iguchi K, Usui S, Yamamoto H, Hirano K. Metabolite Profiles of Flutamide in Serum from Patients with Flutamide-Induced Hepatic Dysfunction. Biol Pharm Bull 2003; 26(10): 1455-1460.

  • 30. Wysowski D K, Freiman J P, Tourtelot J B y Horton M L: Fatal and nonfatal hepatotoxicity asso ciated with flutamide. Ann Intern Med 1993; 118: 8 6 0 – 4 .

  • 31. Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. J Urol 1996; 155: 209-214.

    • Referencias de hepatitis fulminante por Ciproterona:

    • 1. Blake JC, Sawyer AM, Dooley JS.Severe hepatitis caused by cyproterone acetate. Gut 1990; 31: 556-7.

    • 2. Levesque H, Manchon ND, Moore N, Blanckard CE Byar DP, Jordan WP.Fulminant hepatitis due to cyproterone acetate. Lancet 1989; 1: 215-6

    • 3. Wilson JD.Androgens. In: Goodman A, Goodman L, Rall TW, Murad F. Goodman and Gilman. The Pharmacological Basis of Therapeutics. 9ª ed. New York: McGraw-Hill, 1996: 58: 1441-5

    Referencias de apoyo

    • 1. Airhar t RA, Barnett TF, Sullivan JW, Brinkman AO, Jenster G, Ris-Stalpers C. Flutamide therapy for carcinoma of the prostate. South Med J 1978; 71: 798-801

    • 2. Akaza H, Usami M, Kotake T, Koiso K, Aso Y. A randomized phase II trial of flutamide vs. cholormadinone in previouly untreated prostatic cancer. The Japan Futamide Study Group. Jpn J Clin Oncol 1993; 23: 178-85.

    • 3. Azziz R, Gay F. The treatment of hyperandrogenic with oral contraceptives. Sem Reprod Endocrinol 1989;7:246-54

    • 4.  Batukan C, Muderris II. Efficacy of a new contraceptive containing drosperidone and ethinyl estradiol in the long – term treatment of hirsutism. Fertil Steril 2006;85: 436-40.

    • 5. Black M, Raucy J: Acetaminophen, Alcohol and Cytochrome P450. Ann Intern Med 1986; 104:427-436.

    • 6. Blake JC, Sawyer AM, Dooley JS. Severe hepatitis caused by cyproterone acetate. Gut 1990; 31: 556-7.

    • 7. Burton W lee, MD, Stephen I, Stasior D, Etal. Embolismo pulmonar .

    • 8. Carson JL, Strom BL, Duff A, y col: Safety of Nonsteroidal Anti-inflammatory drugs with Respect to Acute Liver Disease. Arch Intern Med 1993; 153:1331-1335.

    • 9. Clínicas Médicas de Norteamérica. Conceptos Actuales de Trombosis. Tendencias Prevalecientes para el Diagnóstico y el Tratamiento. McGraw-Hill Interamericana 1998. p. 445-476.

    • 10. Davidson BL, et als. Color doppler ultrasound to detect proximal leg vein thrombosis. Ann Inter Med 1992; 117: 735-8.

    • 11. Dawson L, Chow E, Morton G. Fulminant hepatic failure associated with bicalutamide. Urology 1997; 49: 283-4

    • 12. Devoto E, Aravena L, Ríos S. Tratamiento del hirsutismo con espironolactona y con espironolactona más dexametasona. Rev Méd Chile 2000;128:868- 75.

    • 13. Devoto E, Aravena L. Eficacia de la flutamida en el tratamiento del hirsutismo. Contribución del uso combinado con anticonceptivos orales en mujeres Normo androgénicas. Rev Méd Chile 2004;132:845-52.

    • 14. Dunn, N (2011 Apr 21). «The risk of deep venous thrombosis with oral contraceptives containing drospirenone.». BMJ (Clinical research ed.) 342: pp. d 2519.

    • 15. Enzo Devoto C. Lucía Aravena C. Actualizacion terapia del hirsutismo. Obst. Gin. 2006; 71(6): 425-431.

    • 16. Esparza R, Cabrera P, Rodríguez F, Juliá G. Tromboembolismo pulmonar. Manual de Neumología y Cirugía Torácica. Madrid: Editores Médicos, S.A. 1.998: 1.027-58.

    • 17. Goldenberg SL, Bruchovsky N, Rennie PS, Begman B, Damber JE, Tomic R. The combination of cyproterone acetate and low dose dethylstelbestrol in the treatment of advanced prostatic carcinoma. J Urol 1988; 140: 1460-5.

    • 18. Goldenberg SL, Bruchovsky N. Use of cyproterone acetate in prostate cancer. Urol Clin North Am 1991; 18: 111-22

    • 19. Goldzieher JW, Zamah NM, Oral contraceptive side effects:1995 Dec; 52(6): 327-35

    • 20. Gonzalez A, Canga F, Cardenas F, Castellano G, Garcia H, Cuenca B, et al. An unusual case of hepatic adenoma in a male. Journal Clin. Gastroenterol. 1994; 19: 179-81.

    • 21. Gregoriou O, Bakas P, Konidaris S, Papadias K, Mathiopoulos D, Creatsas G. The effect of combined oral contraception with or without spironolactone on bone mineral density of hyperandrogenaemic women. Human Reproduction 1993; 8:1807-12.

    • 22. Gronhagen-riska c, hellstrom pe, frose THB. Predisposing factors in hepatitis induced by isoniazid- rifampin treatment of tuberculosis. Am. Rev. Respir. Dis. 1978; 118: 461-

    • 23. Guidelines on diagnosis and management of acute pulmonary embolism. European Heart Journal 2000; 21: 1301-1336.

    • 24. Haid-Fischer F, Haid H. Patología de las Enfermedades venosas, En: Enfermedades de las Venas. Salvat Editores, Barcelona 1984: 33.

    • 25. Haimovici H. Cirugía Vascular Principios y Técnicas., Salvat, 1986.

    • 26. Hammerstein J. Use of cyproterone acetate in the treatment of acne, hirsutism and virilism. J Steroid Biochem 1975;6:827-31. Breckwoldt M. Side-effects and contraindications of treatment with antiandrogens. Androgenization in women, in Hammerstein J, Lachnit -Fixson U, Plewig G (Eds). Excerpta Médica 1980:266-75.

    • 27. Heit J, Silverstein M, Moliv D, Et al . Predictors of survival after Deep vein Thrombosis and Pulmonary embolism . A population Based cohort Study . Arch. Intern. Med. 1999; 159:445-452.

    • 28. Helfer E, Miller JL, Rose LI. Side – effects of spironolactone therapy in the hirsute woman. J Clin Endocrinol Metab 1988;208-11

    • 29. Helfgott sm, sandberg-cook j, zakim d, nestler J. Diclofenac-associated hepatotoxicity. JAMA 1990; 264: 2660-2.

    • 30. Holmes L GW. Deep venous thrombosis and pulmonary embolism: correlative evaluation and therapeutic implications. Am J Roentgenol 1992; 159: 1149-55.

    • 31. Kassem NY, Neri RO, Munroe JS. Effect of flutamide, an antiandrogen, on stage D cancer of the prostate. Clin Pharmacol Ther 1981; 29: 256.

    • 32. Kerlin P, Davis GL, McGill DB, Weiland LH, Adson MA, Sheedy PF 2nd. Hepatic adenoma and focal nodular hyperplasia: clinical, pathologic, and radiologic features. Gastroenterology 1983;84: 994-1002.

    • 33. Koch A, Bourger S, Ziegler S, Dinkell H, Dawres JD, Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgycal intervention. Update of previous meta analisis (Review). British Journal of Surgery 1997;84(6):750-759.

    • 34. Labrie F. Mechanism of action and pure antiandrogen properties of flutamide. Cancer 1993;72:3816-27.

    • 35. Larrey D, Pageaux GP: Genetic Predisposition to Drug- Induced He-patotoxicity. J Hepatol 1997; 26: 12-19.

    • 36. Levesque H, Manchon ND, Moore N, Blanckard CE, Byar DP, Jordan WP. Fulminant hepatitis due to cyproterone acetate. Lancet 1989; 1: 215-6.

    • 37. Lewis jh. Drug-induced Liver Disease. Med. Clin. North. Am. 2000; 84: 1275-311.

    • 38. Lily C. Lee MD, SM, Kaushal S. Clinical manifestation of pulmonary embolism. Emergency Medicine Clinics of North America 2001; 19 (4).

    • 39. Mackler MA, Liber ti JP, Smith MJV. The effect of orchiectomy and various doses of stilbestrol on plasma testosterone levels in patients with carcinoma of the prostate.Invest Urol 1972; 9: 423-5.

    • 40. Makin A., Williams R.: Acetaminophen overdose and acute liver failure: modern management.1996 Yearbook of Intensive Care and Emergency Medicine. J.L.Vincent (Edit.). Springer, Berlin 1996

    • 41. Maria va, victorino rm. Development and validation of a clinical for the diagnosis of drug induced hepatitis. Hepatology 1997; 26: 664-9.

    • 42. Mayo R, Thurner J (1957). "La causa de la ocurrencia predominante sinistral de la trombosis de las venas pélvicas". Angiology 8 (5): 419–27. PMID 13478912.

    • 43. Medicina Basada en la Evidencia .Massachusetts General Hospital. Ed. Marban. Madrid España, 1999. Capitulo : 11. Pags: 245-264.(IV).

    • 44. Moguilewsky M, Fiet J, Tournemine C. Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer. J Steroid Biochem 1986; 24:139-46.

    • 45. Monterrosa A. Anticonceptivos orales combinados. Tercera edición. Bogotá: Editorial Impresos Calidad; 2003

    • 46. Moser KM, Rhodes PG, Hufnagel CG. Chronic unilateral pulmonary artery thrombosis. N Engl. J Med. 1965;272:1195-9.

    • 47. Muderris I I, Bayram F, Guven M. A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride (5 mg/d) in the treatment of hirsutism. Fertil Steril 2000;73: 984-7.

    • 48. Nagorney A, Chen PN, Shin JS, Lin XZ. Hepatic adenoma: an observation from asymptomatic stage to rupture. Hepatogastroenterology 1996; 43:245-8.

    • 49.  Nagorney DM. Benign hepatic tumors: focal nodular hyperplasia and hepatocellular adenoma. World Journal Surg. 1995; 19:13-18.

    • 50. Newton J. Classification and comparison of oral contraceptives containing new generation progestogens. Hum Reprod Update 1995; 1:231-63.

    • 51. Pepper G, Brenner SH, Gabrielove JL. Ketoconazole use in the treatment of ovarian hyperandrogenism. Fertil Steril 1990; 54: 438-44.

    • 52. Piccioli A, Prandoni P, Goldhaber SZ. Epidemiologic characteristics, management, and outcome of deep vein trombosis in a terapy care hospital: The Brigham and Women!s Hospital DVT Registry. Am Heart J 1996; 132:1010 – 4.

    • 53. Pincus MR, Tierno P, Dufour DR. Evaluation of liver function. In: McPherson RA, Pincus MR, eds. Henry's Clinical Diagnosis and Management by Laboratory Methods. 21st ed. Philadelphia, Pa: Saunders Elsevier; 2006: chap 21.

    • 54. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N. Engl. J. Med. 2000; 342(17): 1266-1271

    • 55. Reddy KR, Kligerman S, Levi J et al. Benign and solid tumors of the liver: relationship to sex, age, size of tumors, and outcome. Am. Surg. 2001; 67:173-178.

    • 56. Riordan S., Williams R.: Treatment of hepatic encephalopathy. N. Engl. J. Med. 337:473-1997

    • 57. Rittmaster RS. Treatment of hirsutism. Endocrinologist 1993; 3: 211-8.

    • 58. Rocha E, Martínez F, Monreal M (eds.). Manejo práctico y pautas de actuación en la enfermedad tromboembólica venosa. Madrid: Acción Médica 2004.

    • 59. Rooks JB, Ory WH, Ishak KG, Strauss LT, Greenspan JR, Hill AP, et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 1979;.242: 644-8.

    • 60. Rosenbaum P, Schmidt W, Helmerhorst FM, Wutte W, Rossmanith W, Freundl F, et al. Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestradiol. Eur J Contracept Reprod Health Care 2000;5:16-24

    • 61. Ryan KL, Fedullo PF, Davis GB, Vázquez TE, Moser KM. Perfusion scans under stimate the severity of angiographic and hemodynamic compromise in chronic thrombo.embolic pulmonary hypertension. Chest 1988; 93:1180-5.

    • 62. Sáenz de la Calzada C, et al . Guías de práctica clínica en Trombo embolismo e hipertensión pulmonar. Revista Española de Cardiologia 2001; 54(2): 194-210.

    • 63. Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, et al. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Urology 1995;.45:.7.45-52.

    • 64. Schiano td, lissos tw, ahmed a, siano c, zaitman d, cohn g et al. Lamivudine-stavudine-induced liver failure in hepatitis B cirrhosis. Am. J. Gastroenterol. 1997; 92: 1563-4.

    • 65. Silverstein M, Heit J, Mohr D, et al: Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study. Arch Intern Med 1998; 158:585-593.

    • 66. Simoncini T, Fu XD, Caruso A, et al. Drospirenone increases endothelial nitric oxide synthesis via a combined action on progesterone and mineralocorticoid receptors. Hum Reprod 2007; 22:2325 -2334

    • 67. Smikstein MJ, Knapp GL, Kulig KW y col: Efficacy of Oral N-acetyl-cysteine in the Treatment of Acetaminophen Overdose. Analysis of National Multicenter Study (19761985).NEnglJMedl998;319: 1557-1562.

    • 68. Stricker bh, blok ap, claas fh, vanparys ge, desmet vt. Hepatic injury associated with the use of nitrofurantoin: A clinic pathological study of 52 reported cases. Hepatology 1988; 8: 599-606.

    • 69. Tapson VF, Carroll BA, Davidson BL, Elliott CG, Fedullo PF, Hales CA, et al. The diagnostic approach to acute venous thrombo embolism Clinical practice guideline. American Thoracic Society. Am J Respir. Crit. Care Med 1999; 160: 1043-66.

    • 70. Tela RM, Scott K. Evaluating asymptomatic patients with abnormal liver functions tests results. Am Fam Physician 1996; 53: 2111-2119.

    • 71. Udaya B. S. Prakash. Pulmonary embolism. Mayo Clinic Cardiology Review. Murphy, Joseph G. Segunda edic Capítulo 27. p. 379-406.

    • 72. Venturoli S, Marescalchi O, Colombo F M, Macrelli S, Ravaioli M B, Bagnoli A, et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate – estrogen regimens in the treatment of hirsutism. J.

    • 73. Virchow, RLK Cellular pathology as based upon physiological and pathohistology. 7th

    • 74. Vonberg PP. buller HA, Marsman JWP. Hepatic artery ambolization: Succesfull treatment of multinodular hemangiomatosis of the liver. Eur. J. Pediatr. 1986; 144:.472-74.

    • 75. Weimann A, Ringe B, Klempnauer J et al. Benign liver tumors: differential diagnosis and indications for surgery. World J. Surg. 1997; 21:983-991

    • 76. White WB, Pitt B, Preston RA, et al. Antihypertensive effects of drospirenone with 17 beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 2005;112 :1979 -1984.

    • 77. Wilson JD. Androgens. In: Goodman A, Goodman L, Rall TW, Murad F. Goodman and Gilman. The Pharmacological Basis of Therapeutics. 9ª ed. New York: McGraw-Hill, 1996: 58: 1441-57.

    • 78. Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. J Urol 1996;155:209-12

    • 79. Yamamoto T, Kawarada Y, Yano T, Noguchi T. Mizumoto R. Spontaneus rupture of hemangioma of the liver: Treatment with trans catheter hepatic arterial embolization. Am. J. Gastroenterol. 1991;86: 1645-49.

    • 80. Young RL, Goldzieher JW, Elkind – Hirsch K. The endocrine effects of spironolactone used as an antiandrogen. Fertil Steril 1987;48: 223-8.

    • 81. Zimmerman hj, ishak kg. General aspects of drug induced liver disease. Gastroenterol. Clin. North Am. 1995; 248; 24: 739-57.

    • 82. Zimmerman HJ, Ishak KG. General Aspects of Drug Induced Liver Disease. Gastroenterol. Clin North Am 1995; 24: 739-755.

     

     

    Autor:

    Dra. Mireille Emmanuelle Brambila

    Higiene mental – Trastornos y enfermedades somáticas

    Mexicali Baja California. México 2013

     

    Partes: 1, 2
     Página anterior Volver al principio del trabajoPágina siguiente